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Poor long-term outcomes for many hematologic
conditions that are standard indications in younger
adults have naturally pushed the potentially curative,
albeit toxic, procedure of allogeneic hematopoietic
cell transplantation (HCT) for older adults. The feasi-
bility of allogeneicHCT among older and less fit adults
has been established over the past decade, and the num-
ber of transplants being performed has grown rapidly
for adults 50 years and older. Still, the risks and benefits
of HCT (particularly allogeneic) for older adults
remain poorly defined as the transplant community
has only begun to use crude tools such as comorbidity
to better estimate transplant morbidity and mortality.EPIDEMIOLOGYOF HEMATOLOGIC
MALIGNANCIES IN OLDER ADULTS
The incidence of leukemia rises and the prognosis
declines with each decade of life [1]. For example,
5-year survival for older acute myelogenous leukemia
(AML) patients in registry studies hovers around 3%
compared with 30% in younger adults. Even among
relatively healthy older adults in the seventh decade
of life treated on cooperative group protocols, older
age reduces remission rates and markedly shortens
survival [2]. Adverse biologic features related to aging
presents an argument for allogeneic HCT, but re-
duced tolerance also interferes with long-term disease
control [2].
Feasibility of HCT in Older Adults
Two decades ago, age restrictions often limited
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age [5]. National Marrow Donor Program registry
data illustrate the steady rise in the absolute number
and proportion of older adults undergoing allo-HCT
(Figure 1). Other series have shown the feasibility of
allogeneic HCT for older adults based on survival
fairly similar to younger adults [6-8]. McClune and
colleagues reported the Center for International
Bone Marrow Transplant Registry experience for
standard risk AML and myelodysplastic syndromes
after reduced-intensity conditioning (RIC) allogeneic
HCT for patients 40 years and older. Graft-versus-
host disease (GVHD), relapse, and survival at 2 years
did not differ for older patients compared with youn-
ger patients defined as 40 years or older. To the extent
allogeneic HCT outcomes of older adults do not differ
markedly from younger adults and long-term disease-
free survival can be obtained, feasibility has been estab-
lished. Advances in disease-based therapy, particularly
targeted and less toxic agents, will benefit both young
and old patient alike.
Beyond Feasibility: Major Issues of Allogeneic
HCT in Older Adults
Low uptake of allogeneic HCT
The majority of recipients of allogeneic HCT are
below 50 years of age despite the fact that median
age for most standard disease indications hovers
around 68 to 70 years of age (with acute lymphoblastic
leukemia the exception). Estey and colleagues [9]
quantified the low uptake of allogeneic HCT among
patients 50 years older treated for AML. Only 14 of
99 patients who achieved remission actually went on
to allogeneic HCT, even among this cohort of patients
treated at amajor cancer center removing the barrier of
travel and infrastructure for transplant coordination.
Lack of high-level evidence
The lack of randomized or prospective trials
among older adults comparing HCT to non-HCT
therapy presents a formidable obstacle. Very limited
comparative data exist to quantify the advantages and
risks of allogeneicHCT for older adults. A subset anal-
ysis of transplant eligible patients in first complete
remission (CR) in the study above by Estey suggested
Figure 1. Allogeneic transplants facilitated by the NMDP over time by
recipient age category. The number of transplants has risen most quickly
for recipients 50 years of age and older. (Q 2010 National Marrow
Donor Program, Annual Numbers. Reprinted with permission from
NMDP, available at marrow.org/md)
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ling donor. Farag et al. [10] compared registry out-
comes of adults 60 to 70 years of age with AML in
CR1 for at least 4 months compared with patients
treated on cooperative group chemotherapy protocols.
A benefit in disease-free survival was shown but an
overall survival benefit was not reached.Factors Influencing Growth in Allogeneic HCT
for Older Adults
RIC
RIC or nonmyeloablative regimens for allogeneic
HCT have generally been credited with improved
tolerance and overcoming age barriers. The European
Bone Marrow Transplantation Registry reports 31%
of allogeneic transplants now incorporate RIC [11],
transplant-related mortality ranges from 3% to 55%Table 1. Trends Promoting Hematopoietic Cell Transplant (HCT)
Characteristic
Reduced-intensity conditioning* Fewer acute regimen related tox
Peripheral blood stem cells Reduces time to neutrophil engr
Easier collection of hematopoiet
Supportive care Better infectious monitoring (eg,
Infectious Disease Better infectious disease monito
Growth Factors Facilitate stem cell collection and
Immunosuppression* More tolerable immunosuppress
Human leukocyte antigen (HLA) matching* Better HLA matching reduces po
Donor registries* Merging of registry databases ele
provide resource for unrelate
Patient health Older adults have fewer disabilit
Societal attitudes Patient and physician attitudes ha
CMV indicates cytomegalovirus.
Adapted from Practical Geriatric Oncolgy, Hurria and Cohen, Eds. New York
*Specific for Allogeneic Hematopoietic Cell Transplantation.(68-79) and may be less than myeloablative ap-
proaches. RIC comes at a cost; reducing the condition-
ing regimen intensity and possibly the greater use of
immunosuppression may subject patients to higher
relapse rates [12,13]. Although reduced intensity/
nonmyeloablative conditioning has been widely
credited for the rising use of allogeneic HCT in
older adults, autografts that use myeloablative
regimens for older adults have risen in parallel; other
factors must also contribute (Table 1). Further, the
majority of allogeneic HCT recipients between 50
and 60 years still receive myeloablative conditioning
regimens. The proliferation of regimens and phase II
studies precludes defining an optimal regimen or stan-
dard and may ironically hinder advances.
Nonconditioning factors
A number of nonconditioning factors have accel-
erated the use of allogeneic HCT in older persons
(Table 1). Better infectious diagnosis and management
have been invalulable. Compression of disability has
become well appreciated—older adults today harbor
fewer comorbid conditions or disabilities than in prior
generations and have longer life expectancy and likely
greater years of healthy life [14]. Such changes not
only increase tolerability for older adults but likely
alter patient and physician expectations.
Donors
For older patients, the safety and outcomes related
to hematopoietic cell harvests from older HLA
matched sibling donors has been a concern. The ease
and ready availability of peripherally harvested stem
cells facilitates collection of older donors and has be-
come the de facto standard; between 2008 and 2010,
peripheral blood stem cell grafts comprised 97% of
the allografts for matched sibling donors for older
recipients (preliminary data generously provided by
Center for International Bone Marrow Transplant
Registry but not reviewed by the Advisory or Scientific
Committee). Older donor age marginally reducesfor Older Adults
Example
icities
aftment
ic cells for patients and donors
CMV prophylaxis and early identification)
ring (eg, CMV detection) and better treatments for opportunistic infections
reduce neutropenia phase post-HCT
ion reducing toxicity
st-HCT complications.
ctronically facilitates unrelated donor identification. Cord blood banks
d cord blood.
ies and longer life expectancy allowing more intensive treatment
ve shifted to expect life-prolonging treatment for older adults
: Cambridge Press.
S42 Biol Blood Marrow Transplant 18:S40-S45, 2012A. S. Artzmobilization yields but stem cell products generally
contain an adequate CD341 cell dose [15]. Our own
unpublished data find no affect of older sibling donor
age, after accounting for recipient age, on engraftment
or transplant outcomes.
It is unknown whether a younger matched unre-
lated donor represents a better alternative to an older
matched sibling donor. The McClune registry analy-
sis of older AML and myelodysplastic syndromes after
RIC showed that matched siblings improved disease-
free survival and approached better overall survival
(P 5 .08) relative to well-matched unrelated donors.
For bone marrow transplants, older donor age has
been shown in some but not all analyses to worsen
outcomes [16,17]. To the extent reduced cell doses
from older bone marrow allografts functions as
a pathway to mediate worse outcomes, peripheral
blood stem cell grafts may abrogate age-related har-
vest problems. Pulsipher [18] showed at least for unre-
lated donor peripheral blood stem cell transplants,
higher CD341 cell dose, but not older donor age,
influenced nonrelapse mortality (NRM) and OS.
The data on cord blood units in older adults are of in-
terest but very limited [19,20]. We advocate using
matched sibling donors when available, at least up to
the age of 75 years if cleared and a CD34 cell dose
of 2  106 CD34 cells/kg of recipient weight can be
achieved.
Patient-Specific Factors
If we assume allogeneic HCT controls disease
equally well for older adults compared with younger
adults (and this is a major assumption), standard dis-
ease indications can be followed. The main challenge
rests in defining acceptable treatment-related morbid-
ity and mortality for individual patients. Geriatrics
conceptualizes patient-specific factors that influence
tolerance as vulnerability. Advanced age, comorbidity,
and functional status are separate, but related domains
of vulnerability typically considered in the transplant
setting.
Age
The influence of older age on HCT outcome
remains controversial, and probably overemphasized.
Most of the debate revolves around patients aged 50
to 70 years of age fare ‘‘worse’’. Studies using myeloa-
blative conditioning for allogeneic HCT 1 to 2 de-
cades ago demonstrated that older age translated into
greater NRM from regimen toxicities and GVHD
[21-23]. After RIC, older age may impart a small or
minimal influence on outcomes. Studies pooling data
across centers, such as registry studies, indicate
NRM of around 20% to 35% at 1 to 2 years for
older adults. GVHD may be more common among
older adults [24] and increase the risk of NRM.Only a small proportion of eligible older patients
with transplant indications undergo HCT, which
limits generalization about tolerance in older adults.
Such patients may be selected for better health status
and the availability of social and financial resources.
For example, we found that after an RIC regimen,
age 50 years and older, showed only a marginal associ-
ation with worse NRM relative to younger adults [25].
After adjusting for comorbidity, performance status,
and disease features, the influence of older age on
NRM actually became stronger. Still, age by itself
lacks adequate precision, at least between 50 to 70 or
75 years of age, and thus the call to study ‘‘biologic
age’’ rather than ‘‘chronologic age.’’
The pressing question facing physicians and pa-
tients alike today is whether an older patient will
have acceptable transplant tolerance (less vulnerabil-
ity) to allow curative intent therapy. Better character-
izing heterogeneity or ‘‘biologic age’’ will alos permit
more accurate comparisons in nonrandomized studies
between transplant and nontransplant outcomes.Comorbidity
Indexes of Comorbid conditions have become
widely used tools to quantify vulnerability. Most in-
struments report a composite score based on medical
history with or without objective testing, excluding
the primary malignancy [26,27]. More vulnerability
by the Charlson Comorbidity Index was initially
shown to have prognostic value for NRM by the
Seattle group but most patients had few abnormalities
(ie, ceiling effect of instrument) [28-30]. Investigators
at Seattle capitalized on the extensive standardized
pretransplant evaluation to create the hematopoietic-
cell transplantation-comorbidity index (HCT-CI or
Sorror score) by integrating new conditions (eg, infec-
tion, obesity) and objective testing (eg, pulmonary
function testing) to the Charlson Comorbidity Index.
At 2 years, the HCT-CI predicted for increased
NRM (hazard ratio [HR]5 3.5, 95% confidence inter-
val [CI]: 2.0-6.3) and inferior survival (HR5 2.7, 95%
CI: 1.8-4.1). The HCT-CI quickly emerged as widely
used comorbidity tool for transplant if not other hema-
tologic malignancies [30]. The precise degree to which
the HCT-CI predicts for poor outcomes has been
debated. Interestingly, higher comorbidity may better
predict for OS rather than NRM, and thus may be
also track with disease or other nonvulnerability
parameters [25,31-33]. Nevertheless, these data by
Sorror and colleagues helped frame a paradigm shift,
long appreciated in other fields, away from age alone,
and toward patient specific factors for vulnerability.
More sensitive comorbidity tools such as the
comprehensive illness rating scale-geriatrics may be
more sensitive but more sensitive tools require formal
testing for prognostic utility (Figure 2).
Figure 2. Limitations in performance status and comorbidity, applying
different comorbidity indexes before allogeneic transplantation in adults
50 years and older. ECOG, Eastern Cooperative Oncology Group
Performance Status; CCI, Charlson Comorbidity Index; KF, Kaplan-
Feinstein Scale; HCT, CI-Hematopoietic Cell Transplantation Comor-
bidity Index; CIRS-G, Cumulative Illness Rating Scale-Geriatrics.
(Swanson K et al, Tandem BMT 2009).
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Impaired functional status, as measured either by
Karnofsky or the Eastern Cooperative Oncology
Group Performance Score (PS), consistently worsens
transplant outcomes. Older adults with suboptimal
PS such as Karnofsky\70% or Eastern Cooperative
Oncology Group (ECOG) PS of 2 or less are fre-
quently excluded from transplant. For example,
ECOG PS of 2 strongly predicts for poor outcome
but is infrequent, found in\10% of patients undergo-
ing RIC allogeneic HCT [25,34]. In the registry
analysis by McClune, only 16% of patients 65 years
and older had a karnofsky PS of 70% or less but
prognostically this group fared worse.
The clinical observation that a patient looks
‘‘younger than his/her age’’ reflects the inability to
quantify health with current measures. More robust
measures of functional status in those with a
karnfosky PS of 80% or more would lend needed
objectivity. As impaired function independent of co-
morbidity, predicts toxicity and survival in older can-
cer patients, more comprehensive functional tools
may be invaluable.
Primary measures of functional status in the geriat-
ric toolbox are scales of Activities of Daily Living (eg,
bathing, toileting) and Instrumental Activities of Daily
Living (IADL).Loss of IADLs (eg, shopping,managing
finances) may result in the inability to live indepen-
dently for older adults. Surprisingly, almost 40% of
older adults evaluated in a geriatric oncology clinic
had IADL limitations despite an ECOG PS of \2
[35], and IADL limitations predicts for worse survival
in older AML patients, independent of PS and age
[36].We have only recently begun exploring such mea-sures in older allogeneic transplant recipients but the
prognostic value remains unknown [37].
Another approach has been to combine measures
that may be additive or synergistic. Adding PS to co-
morbidity enhances HCT prognostication [25,33].
Albeit simple, this may be the first step in formulating
an accurate and broadly applicable prognostic index
for transplant tolerance in older adults.
Comprehensive Geriatric Assessment—The
Wave of the Future?
Accurate prognostication of morbidity and mortal-
ity will require tabulation of vulnerability outside of
HCT-CI andPS.A comprehensivegeriatric assessment
(CGA) encompasses a multidisciplinary evaluation of
comorbid disease, physical function, cognition, nutri-
tional status, polypharmacy, andothers.Althougha typ-
ical CGA is time consuming, screening tools or simpler
methods tailored for the relatively healthy candidates
for allogeneic HCT can be performed. One might
expect transplant recipients to be too healthy for
a CGA to identify limitations since the mainstay of
CGA has been for adults 70 years and older. Our expe-
rience with a CGA for patients 50 years and older
undergoing allogeneic is informative. Several instru-
ments detected more vulnerability than standard mea-
sures of HCT-CI or PS including comprehensive
illness rating scale-geriatrics (Figure 2), the short-
form 36 quality-of-life self-report survey and the frailty
index [37]. For example, 81% met prefrail criteria and
24% fell into the true frail category applying established
frailty criteria [38]. These data argue against the tradi-
tional notion that older patients undergoing allo-
HCT have robust health, at least in the modern era of
RIC.Themedian time required by the staff to interview
subjects was only 20 minutes, as most of the data are
self-report or standard transplant testing.
Additional benefits will accrue by better character-
izing vulnerabilities. Investigators may prospectively
test strategies to reduce morbidity targeted to the vul-
nerability (eg, exercise program for functional
impairments). The availability of numerous nontrans-
plant databases rich in disease and patient-specific
factors can be maximally leveraged to produce higher
quality evidence to guide practice.
Biomarkers
We have found that elevated C-reactive protein
before conditioning predicts for increased toxicity
and NRM but not relapse, independent of HCT-CI
and PS [32]. Elevated pre-HCT serum ferritin may en-
hance prognostication [39]. If validated, the objective
and reproducible nature of such simple biomarkers
may be an invaluable adjunct to other vulnerability
measures.
Other domains such as nutrition (often qualified by
10% of weight loss) and cognitive assessment require
S44 Biol Blood Marrow Transplant 18:S40-S45, 2012A. S. Artztesting as well may be valuable. Known pathways to re-
duce complications of cognitive impairment such as de-
lirium exist and could be easily applied to HCT. Even
among relatively young transplant recipients, delirium
occurs in up to 50% of allogeneic HCT recipients [40].
Recommendations
Absent a strong body of data, a few guiding princi-
ples can be proposed for allogeneic HCT for older
adults. Disease indications for older adults should gen-
erally follow standard criteria and participation in clin-
ical trials is highly encouraged. The disease, health
status, and center expertise all influence conditioning
regimen selection, as there are little data to support
the superiority in survival for any conditioning ap-
proach. For donors, a matched sibling donor if medi-
cally cleared and 75 years or younger may be
preferable over a younger matched unrelated donor.
For evaluation of vulnerability and tolerance, perfor-
mance status can be useful to exclude patients. One
should proceed with great caution if at all if the PS is
2 or Karnofsky of 70% or less. We are very restrictive
in patients 70 years and older. The HCT-CI should be
calculated but exclusions should not be based solely on
the HCT-CI alone. Poorly compensated organ dys-
function (eg, renal, cardiac, or pulmonary) are usually
best avoided. Other markers of vulnerability hold con-
siderable promise and will likely enable more accurate
risk assignment.ACKNOWLEDGMENTS
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